Skip to content
1887

Journal of Medical Microbiology logo Journal of Medical Microbiology

Volume 74, Issue 7

The bibliometric analysis of documents concerning the relationship between the microbiota and urological malignancies Open Access

Abstract

The microbiota, which has a major impact on both health and illness, has recently become one of the most popular research topics.

To the best of our knowledge, no research has undertaken a bibliometric analysis of publications examining the connection between microbiome and urological cancer to date. In this respect, it is thought that our study will contribute to the literature.

The purpose of this study is to raise awareness of the topic by performing a bibliometric analysis of the publications examining the connection between the microbiota and the most common urological cancers, including bladder, prostate, and kidney cancers.

All publications about prostate, renal and bladder cancers and microbiota indexed in Web of Science between 2000 and 2024 were included in the study.

A total of 310 publications were obtained. Before 2018, there were only three or fewer publications annually; however, following 2018, the number of publications increased rapidly, reaching a peak of 77 in 2024. The USA led with 98 (31.61%) documents, followed by China (60, 19.35%) and Italy (31, 10%). With 19 publications, Hirotsugu Uemura is the most contributing author, followed by Norio Nonomura with 17. Prostate cancer accounted for 45.48% of the publications, bladder cancer for 36.77% and kidney malignancies for 17.64%.

Despite the fact that microbiota has been known for 80 years, research on the connection between microbiota and cancer accelerated after the completion of the Human Microbiome Project. The number of studies examining the connection between urological cancer and microbiota peaked in 2024 and is probably going to rise. More research is required on this topic, since the correlation between microbiota and especially prostate and bladder malignancies raises the possibility that variations in microbiota may be utilized in diagnosis, treatment and prognosis.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): bibliometric , bladder , cancer , microbiota , prostate and renal
© 2025 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License.
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.002041
2025-07-02
2025-07-10
Loading full text...

Full text loading...

/deliver/fulltext/jmm/74/7/jmm002041.html?itemId=/content/journal/jmm/10.1099/jmm.0.002041&mimeType=html&fmt=ahah

References

  1. Zhu B, Wang X, Li L. Human gut microbiome: the second genome of human body. Protein Cell 2010; 1:718–725 [View Article] [PubMed]
     [Google Scholar]
  2. Hou K, Wu Z-X, Chen X-Y, Wang J-Q, Zhang D et al. Microbiota in health and diseases. Signal Transduct Target Ther 2022; 7:135 [View Article] [PubMed]
     [Google Scholar]
  3. Afzaal M, Saeed F, Shah YA, Hussain M, Rabail R et al. Human gut microbiota in health and disease: unveiling the relationship. Front Microbiol 2022; 13:999001 [View Article] [PubMed]
     [Google Scholar]
  4. Constantin M, Chifiriuc MC, Mihaescu G, Corcionivoschi N, Burlibasa L et al. Microbiome and cancer: from mechanistic implications in disease progression and treatment to development of novel antitumoral strategies. Front Immunol 2024; 15:1373504 [View Article] [PubMed]
     [Google Scholar]
  5. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin 2024; 74:12–49 [View Article] [PubMed]
     [Google Scholar]
  6. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74:229–263 [View Article] [PubMed]
     [Google Scholar]
  7. Donthu N, Kumar S, Mukherjee D, Pandey N, Lim WM. How to conduct a bibliometric analysis: an overview and guidelines. Journal of Business Research 2021; 133:285–296 [View Article]
     [Google Scholar]
  8. Vicinanza R, Zhang Y, Henning SM, Li Z, Heber D. Urolithin A and ellagic acid inhibit prostate cancer through different molecular mechanisms: implications of gut microbiome metabolism for cancer prevention. FASEB J 2011; 25: [View Article]
     [Google Scholar]
  9. Sfanos KS, Yegnasubramanian S, Nelson WG, De Marzo AM. The inflammatory microenvironment and microbiome in prostate cancer development. Nat Rev Urol 2018; 15:11–24 [View Article] [PubMed]
     [Google Scholar]
  10. Bučević Popović V, Šitum M, Chow CET, Chan LS, Roje B et al. The urinary microbiome associated with bladder cancer. Sci Rep 2018; 8:12157 [View Article] [PubMed]
     [Google Scholar]
  11. Shrestha E, White JR, Yu S-H, Kulac I, Ertunc O et al. Profiling the urinary microbiome in men with positive versus negative biopsies for prostate cancer. J Urol 2018; 199:161–171 [View Article]
     [Google Scholar]
  12. de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012; 13:607–615 [View Article] [PubMed]
     [Google Scholar]
  13. Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol 2014; 12:661–672 [View Article] [PubMed]
     [Google Scholar]
  14. Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 2012; 491:254–258 [View Article] [PubMed]
     [Google Scholar]
  15. Wu S, Rhee K-J, Albesiano E, Rabizadeh S, Wu X et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 2009; 15:1016–1022 [View Article] [PubMed]
     [Google Scholar]
  16. Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 2013; 14:207–215 [View Article] [PubMed]
     [Google Scholar]
  17. Gilbert JA, Blaser MJ, Caporaso JG, Jansson JK, Lynch SV et al. Current understanding of the human microbiome. Nat Med 2018; 24:392–400 [View Article] [PubMed]
     [Google Scholar]
  18. Global Burden of Disease 2019 Cancer Collaboration Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. JAMA Oncol 2022; 8:420–444 [View Article] [PubMed]
     [Google Scholar]
  19. Mingdong W, Xiang G, Yongjun Q, Mingshuai W, Hao P. Causal associations between gut microbiota and urological tumors: a two-sample mendelian randomization study. BMC Cancer 2023; 23:854 [View Article] [PubMed]
     [Google Scholar]
  20. Hungate RE. Studies on cellulose fermentation: i. The culture and physiology of an anaerobic cellulose-digesting bacterium. J Bacteriol 1944; 48:499–513 [View Article] [PubMed]
     [Google Scholar]
  21. Haffajee D, Socransky SS. Microbiota on oral mucous membranes of healthy and oral cancer subjects. J Dent Res 2002; 81:149
     [Google Scholar]
  22. The Integrative HMP (iHMP) Research Network Consortium The integrative human microbiome project. Nature 2019; 569:641–648 [View Article] [PubMed]
     [Google Scholar]
  23. Zyoud SH, Al-Jabi SW, Amer R, Shakhshir M, Shahwan M et al. Global research trends on the links between the gut microbiome and cancer: a visualization analysis. J Transl Med 2022; 20:83 [View Article] [PubMed]
     [Google Scholar]
  24. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68:394–424 [View Article] [PubMed]
     [Google Scholar]
  25. Luo L-S, Luan H-H, Zhang P, Jiang J-F, Zeng X-T et al. The disease burden of bladder cancer and its attributable risk factors in five Eastern Asian countries, 1990-2019: a population-based comparative study. BMC Public Health 2024; 24:2404 [View Article] [PubMed]
     [Google Scholar]
  26. Cirillo L, Innocenti S, Becherucci F. Global epidemiology of kidney cancer. Nephrol Dial Transplant 2024; 39:920–928 [View Article] [PubMed]
     [Google Scholar]
  27. Hassanipour-Azgomi S, Mohammadian-Hafshejani A, Ghoncheh M, Towhidi F, Jamehshorani S et al. Incidence and mortality of prostate cancer and their relationship with the Human Development Index worldwide. Prostate Int 2016; 4:118–124 [View Article] [PubMed]
     [Google Scholar]
  28. Satam H, Joshi K, Mangrolia U, Waghoo S, Zaidi G et al. Next-generation sequencing technology: current trends and advancements. Biology 2023; 12:997 [View Article] [PubMed]
     [Google Scholar]
  29. Hajjo R, Sabbah DA, Al Bawab AQ. Unlocking the potential of the human microbiome for identifying disease diagnostic biomarkers. Diagnostics 2022; 12:1742 [View Article] [PubMed]
     [Google Scholar]
  30. Ece G, Aktaş A, Caner A, Sağlık İ, Kula Atik T et al. The urogenital system microbiota: is it a new gamechanger in urogenital cancers?. Microorganisms 2025; 13:315 [View Article] [PubMed]
     [Google Scholar]
  31. Wu P, Zhang G, Zhao J, Chen J, Chen Y et al. Profiling the urinary microbiota in male patients with bladder cancer in China. Front Cell Infect Microbiol 2018; 8:167 [View Article] [PubMed]
     [Google Scholar]
  32. Golombos DM, Ayangbesan A, O’Malley P, Lewicki P, Barlow L et al. The role of gut microbiome in the pathogenesis of prostate cancer: a prospective, pilot study. Urology 2018; 111:122–128 [View Article] [PubMed]
     [Google Scholar]
  33. Porter CM, Shrestha E, Peiffer LB, Sfanos KS. The microbiome in prostate inflammation and prostate cancer. Prostate Cancer Prostatic Dis 2018; 21:345–354 [View Article] [PubMed]
     [Google Scholar]
  34. Salgia NJ, Bergerot PG, Maia MC, Dizman N, Hsu J et al. Stool microbiome profiling of patients with metastatic renal cell carcinoma receiving anti-PD-1 immune checkpoint inhibitors. Eur Urol 2020; 78:498–502 [View Article] [PubMed]
     [Google Scholar]
  35. Liss MA, White JR, Goros M, Gelfond J, Leach R et al. Metabolic biosynthesis pathways identified from fecal microbiome associated with prostate cancer. Eur Urol 2018; 74:575–582 [View Article]
     [Google Scholar]
  36. Matsushita M, Fujita K, Hayashi T, Kayama H, Motooka D et al. Gut microbiota-derived short-chain fatty acids promote prostate cancer growth via IGF1 signaling. Cancer Res 2021; 81:4014–4026 [View Article] [PubMed]
     [Google Scholar]
  37. Sfanos KS, Markowski MC, Peiffer LB, Ernst SE, White JR et al. Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies. Prostate Cancer Prostatic Dis 2018; 21:539–548 [View Article] [PubMed]
     [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.002041
Loading
The bibliometric analysis of documents concerning the relationship between the microbiota and urological malignancies
J. Med. Microbiol. 74, 002041 (2025); https://doi.org/10.1099/jmm.0.002041
/content/journal/jmm/10.1099/jmm.0.002041
/content/journal/jmm/10.1099/jmm.0.002041
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error